Detectable Serum Pro-opiomelanocortin-Derived Peptides in Bromocriptine-Sensitive Cushing Disease

Abstract:We report a rare case of Cushing disease in whom plasma adrenocorticotropic hormone (ACTH) has been continuously suppressed with a low daily dose of bromocriptine for over 4 years. A 78-year-old woman presenting with hypercortisolism (65.0 μg/dL at 8:00 am) with an exceedingly high concentr

[1]  M. Minetto,et al.  The corticotrophin‐releasing hormone test is the most reliable noninvasive method to differentiate pituitary from ectopic ACTH secretion in Cushing's syndrome , 2003, Clinical endocrinology.

[2]  M. Korbonits,et al.  Optimal response criteria for the human CRH test in the differential diagnosis of ACTH-dependent Cushing's syndrome. , 2002, The Journal of clinical endocrinology and metabolism.

[3]  A. Saiardi,et al.  Absence of dopaminergic control on melanotrophs leads to Cushing's-like syndrome in mice. , 1998, Molecular endocrinology.

[4]  R. Magallón,et al.  The long-term outcome of pituitary irradiation after unsuccessful transsphenoidal surgery in Cushing's disease. , 1997, The New England journal of medicine.

[5]  N. Colombo,et al.  MR of corticotropin-secreting pituitary microadenomas. , 1994, AJNR. American journal of neuroradiology.

[6]  K. Takakura,et al.  Selective venous sampling directly from cavernous sinus in Cushing's syndrome. , 1993, The Journal of clinical endocrinology and metabolism.

[7]  T. Mune,et al.  Cortisol-suppressible dexamethasone-nonsuppressible cyclic Cushing's disease with evidence of clinical and biochemical remission with bromocriptine. , 1991, Endocrinologia japonica.

[8]  S. Arimori,et al.  A case of Cushing's disease successfully treated with bromocriptine. , 1990, Japanese journal of medicine.

[9]  G. Besser,et al.  MEGAVOLTAGE PITUITARY IRRADIATION IN THE MANAGEMENT OF CUSHING'S DISEASE AND NELSON'S SYNDROME: LONG‐TERM FOLLOW‐UP , 1989, Clinical endocrinology.

[10]  A. Grossman,et al.  A BROMOCRIPTINE‐RESPONSIVE CORTICOTROPH ADENOMA SECRETING α‐MSH IN A PATIENT WITH CUSHING'S DISEASE , 1988, Clinical endocrinology.

[11]  C. Francalanci,et al.  Cushing’s disease: clinical and laboratory response to bromocriptine therapy , 1984, Journal of endocrinological investigation.

[12]  M. Nagata,et al.  Identification of source of excessive ACTH production by improved selective venous sampling: simultaneous assay of PRL as a pituitary marker. , 1984, Endocrinologia japonica.

[13]  M. Tagliaferri,et al.  Cushing’s disease and marked hyperprolactinemia in a patient with a pituitary macroadenoma: effectiveness of bromocriptine treatment , 1984, Journal of endocrinological investigation.

[14]  S. Lamberts,et al.  Adrenocorticotropin-secreting pituitary adenomas originate from the anterior or the intermediate lobe in Cushing's disease: differences in the regulation of hormone secretion. , 1982, The Journal of clinical endocrinology and metabolism.

[15]  J. Deakin,et al.  Influence of N-terminal acetylation and C-terminal proteolysis on the analgesic activity of beta-endorphin. , 1980, The Biochemical journal.

[16]  D. Schteingart,et al.  Sustained remission of Cushing's disease with mitotane and pituitary irradiation. , 1980, Annals of internal medicine.

[17]  R. Mains,et al.  Structure and biosynthesis of pro-adrenocorticotropin/endorphin and related peptides. , 1980, Endocrine reviews.

[18]  M. Laudat,et al.  Treatment of Cushing's disease by O,p'DDD. Survey of 62 cases. , 1979, The New England journal of medicine.

[19]  J. Melby,et al.  Treatment of Cushing's syndrome with trilostane (WIN 24,540), an inhibitor of adrenal steroid biosynthesis. , 1978, The Journal of clinical endocrinology and metabolism.

[20]  K. Tanaka,et al.  The nature of the immunoreactive lipotropins in human plasma and tissue extracts. , 1978, The Journal of clinical investigation.

[21]  C. McMartin,et al.  Purification and characterization of porcine corticotrophin-like intermediate lobe peptide. , 1974, The Journal of endocrinology.